EMEA-001741-PIP01-14-M07 - paediatric investigation plan
Upadacitinib
PIPHuman
Key facts
- Invented name
- Rinvoq
- Active Substance
- Upadacitinib
- Therapeutic area
- Immune system disorders
- Decision number
- P/0010/2024
- PIP number
- EMEA-001741-PIP01-14-M07
- Pharmaceutical form(s)
- Age-appropriate oral solid dosage form
- Age-appropriate oral liquid dosage form
- Prolonged-release tablet
- Condition(s) / indication(s)
- Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)
- Route(s) of administration
- Oral use
- Contact for public enquiries
Abbvie Limited
Email: paediatricteam@abbvie.com
Tel. +44 (0)1628 408248- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date